Tag: Biopharma Perspective
-
How Ziihera Targets HER2 Differently From Trastuzumab
Ziihera binds two HER2 extracellular domains simultaneously, promoting receptor internalization and immune-mediated killing through a mechanism distinct from trastuzumab and Enhertu.
-
Genentech Bets $2.3 Billion on Hanmi’s Muscle-Preserving Obesity Drug
Genentech licensed Hanmi’s HM17321 in a deal worth up to $2.3 billion, adding a non-incretin obesity candidate designed to reduce fat while preserving muscle.
-
How HM17321 Could Preserve Muscle During Weight Loss
HM17321 uses UCN2–CRFR2 signaling to target fat loss and muscle preservation through a non-incretin mechanism, offering a different approach to obesity treatment.
-
LEO Pharma Bets Up to $435 Million on Oral Therapy for Rare Sunlight-Induced Pain
LEO Pharma is acquiring global rights to dersimelagon from Tanabe Pharma in a deal worth up to $435 million. The oral MC1R agonist has completed Phase 3 development in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) and has already been submitted to the FDA.
-
Three Different Ways to Reduce Phototoxic Pain in EPP and XLP
Dersimelagon, Scenesse and bitopertin approach phototoxic pain through fundamentally different strategies. This BP Science explainer compares MC1R-driven photoprotection with upstream reduction of protoporphyrin IX (PPIX) production in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
-
Eli Lilly Moves Into Trans-Amplifying RNA Vaccines With Amplitude Deal
Eli Lilly is expanding into next-generation RNA vaccines through a collaboration with Amplitude Therapeutics, gaining access to a trans-amplifying RNA platform designed to separate the replicase from the antigen payload and support multiple infectious-disease vaccine programs.
-
Johnson & Johnson Wins EU Approval for Tecvayli Plus Darzalex in Multiple Myeloma
The European Commission approved Tecvayli plus Darzalex for adults with relapsed or refractory multiple myeloma after at least one prior therapy, supported by Phase 3 MajesTEC-3 data showing an 83% reduction in the risk of progression or death versus DPd or DVd.
-
Two Different Ways to Fight Multiple Myeloma
This BP Science explainer compares two mechanistically distinct multiple myeloma strategies: Zenbexus-driven cereblon-mediated protein degradation and Tecvayli-based BCMA×CD3 T-cell redirection, with daratumumab providing additional CD38 targeting in both regimens.
-
Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win
Moderna and Merck’s personalized mRNA cancer therapy intismeran met both recurrence-free survival and distant metastasis-free survival endpoints in Phase 3 melanoma, marking a major milestone for individualized mRNA-based cancer treatment.
-
Amylyx Turns GLP-1 Biology in the Opposite Direction
Avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo in patients with post-bariatric hypoglycemia.